Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase I Study of Gefitinib and Capecitabine in Patients With Advanced Solid Tumors

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase I	Treatment	Completed	18 and over	NCI	UCHSC-01479 NCI-3858, NCT00039390, 3858

Trial Description

Purpose:

Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib and capecitabine may kill more tumor cells.

This phase I trial is studying the side effects and best dose of gefitinib and capecitabine in treating patients with advanced solid tumors.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• At least 4 weeks since chemotherapy or radiation therapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive gefitinib by mouth once a day for 2 weeks and capecitabine by mouth twice a day for 3 weeks. Treatment may be repeated every 4 weeks for as long as benefit is shown.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

University of Colorado Cancer Center at UC Health Sciences Center

Michele Basche, MD, Protocol chair		Ph: 720-848-0300; 800-473-2288

Registry Information
Official Title		A Phase I Trial Of ZD1839 With Capecitabine In Patients With Advanced Solid Tumors (formerly a Phase I Trial of ZD1839 with Capecitabine and Celecoxib)
Trial Start Date		2002-07-18
Registered in ClinicalTrials.gov		NCT00039390
Date Submitted to PDQ		2002-04-22
Information Last Verified		2005-05-25
NCI Grant/Contract Number		CA46934

Back to Top